

# Massimo Gennarelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9188719/publications.pdf>

Version: 2024-02-01

218  
papers

10,803  
citations

31976

53  
h-index

42399

92  
g-index

232  
all docs

232  
docs citations

232  
times ranked

14093  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association studies on Northern Italy isolated populations provide further support concerning genetic susceptibility for major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2023, 24, 135-148.	2.6	1
2	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 46-54.	2.6	4
3	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2022, 55, 86-95.	0.7	19
4	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. <i>European Neuropsychopharmacology</i> , 2022, 55, 112-157.	0.7	7
5	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	27.8	929
6	Genetic Dissection of Temperament Personality Traits in Italian Isolates. <i>Genes</i> , 2022, 13, 4.	2.4	2
7	Extracellular clusterin limits the uptake of $\alpha$ -synuclein fibrils by murine and human astrocytes. <i>Glia</i> , 2021, 69, 681-696.	4.9	32
8	Biological correlates of early life stressful events in major depressive disorder. <i>Psychoneuroendocrinology</i> , 2021, 125, 105103.	2.7	23
9	Investigating an in silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression. <i>Pharmacogenomics Journal</i> , 2021, 21, 85-93.	2.0	1
10	Alterations observed in the interferon $\alpha$ and $\beta$ signaling pathway in MDD patients are marginally influenced by cis-acting alleles. <i>Scientific Reports</i> , 2021, 11, 727.	3.3	1
11	Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19. <i>Pharmacological Research</i> , 2021, 164, 105402.	7.1	1
12	Classification of Psychoses Based on Immunological Features: A Machine Learning Study in a Large Cohort of First-Episode and Chronic Patients. <i>Schizophrenia Bulletin</i> , 2021, 47, 1141-1155.	4.3	11
13	Establishment and characterization of induced pluripotent stem cell (iPSCs) line UNIBSi014-A from a healthy female donor. <i>Stem Cell Research</i> , 2021, 51, 102216.	0.7	2
14	Intermediate lengths of the C9ORF72 hexanucleotide repeat expansion may synergistically contribute to attention deficit hyperactivity disorder in child and his father: case report. <i>Neurocase</i> , 2021, 27, 138-146.	0.6	2
15	Evidence of an interaction between <i>FXR1</i> and <i>GSK3<math>\beta</math></i> polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics. <i>European Psychiatry</i> , 2021, 64, e39.	0.2	6
16	Leucine-rich repeat kinase 2-related functions in GLIA: an update of the last years. <i>Biochemical Society Transactions</i> , 2021, 49, 1375-1384.	3.4	6
17	Whole Blood Transcriptome Characterization of 3xTg-AD Mouse and Its Modulation by Transcranial Direct Current Stimulation (tDCS). <i>International Journal of Molecular Sciences</i> , 2021, 22, 7629.	4.1	4
18	Molecular Biomarkers of Electroconvulsive Therapy Effects and Clinical Response: Understanding the Present to Shape the Future. <i>Brain Sciences</i> , 2021, 11, 1120.	2.3	11

#	ARTICLE	IF	CITATIONS
19	Investigating the Role of Leukocyte Telomere Length in Treatment-Resistant Depression and in Response to Electroconvulsive Therapy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1100.	2.5	3
20	Inflammation-related microRNAs are involved in stressful life events exposure and in trauma-focused psychotherapy in treatment-resistant depressed patients. <i>HÅrgre Utbildning</i> , 2021, 12, 1987655.	3.0	16
21	Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RANdomized, participant and rater-blinded, controlled trial (PANDORA) Tj ETQq1 1 0.7843d 4 rgBT 4 Overloc		
22	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 921-932.	3.2	22
23	Childhood trauma and glucose metabolism in patients with first-episode psychosis. <i>Psychoneuroendocrinology</i> , 2020, 113, 104536.	2.7	15
24	Correlations between immune and metabolic serum markers and schizophrenia/bipolar disorder polygenic risk score in first-episode psychosis. <i>Microbial Biotechnology</i> , 2020, 14, 507-511.	1.7	15
25	P.264 Association of single nucleotide polymorphisms in the 3' untranslated region of SLC1A2 with major depressive disorder and relative endophenotypes. <i>European Neuropsychopharmacology</i> , 2020, 40, S150-S151.	0.7	0
26	Genetic counselling and testing for inherited dementia: single-centre evaluation of the consensus Italian DIAfN protocol. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 152.	6.2	7
27	Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments. <i>Genes</i> , 2020, 11, 1089.	2.4	17
28	Behavioral and Psychological Symptoms of Dementia (BPSD): Clinical Characterization and Genetic Correlates in an Italian Alzheimer's Disease Cohort. <i>Journal of Personalized Medicine</i> , 2020, 10, 90.	2.5	15
29	The Emerging Role of SGK1 (Serum- and Glucocorticoid-Regulated Kinase 1) in Major Depressive Disorder: Hypothesis and Mechanisms. <i>Frontiers in Genetics</i> , 2020, 11, 826.	2.3	28
30	Assessment of haptoglobin alleles in autism spectrum disorders. <i>Scientific Reports</i> , 2020, 10, 7758.	3.3	2
31	Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. <i>Drug Development Research</i> , 2020, 81, 754-761.	2.9	15
32	Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response. <i>Drug Development Research</i> , 2020, 81, 593-599.	2.9	14
33	miR-146a Plasma Levels Are Not Altered in Alzheimer's Disease but Correlate With Age and Illness Severity. <i>Frontiers in Aging Neuroscience</i> , 2020, 11, 366.	3.4	17
34	Generation of two human induced pluripotent stem cell lines, UNIBSi012-A and UNIBSi013-A, from two patients with treatment-resistant depression. <i>Stem Cell Research</i> , 2020, 49, 102104.	0.7	1
35	miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 82, 102-109.	3.1	76
36	F49GENETIC DETERMINANTS OF CIRCULATING VEGF LEVELS IN MAJOR DEPRESSIVE DISORDER. <i>European Neuropsychopharmacology</i> , 2019, 29, S1135-S1136.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates. <i>Frontiers in Pharmacology</i> , 2019, 10, 402.	3.5	35
38	BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients. <i>Journal of ECT</i> , 2019, 35, 189-194.	0.6	19
39	Î±-Synuclein and Glia in Parkinsonâ€™s Disease: A Beneficial or a Detrimental Duet for the Endo-Lysosomal System?. <i>Cellular and Molecular Neurobiology</i> , 2019, 39, 161-168.	3.3	40
40	Next Generation Sequencing Analysis in Early Onset Dementia Patients. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 243-256.	2.6	29
41	Immune and metabolic alterations in first episode psychosis (FEP) patients. <i>Brain, Behavior, and Immunity</i> , 2018, 70, 315-324.	4.1	31
42	Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 610-618.	2.6	12
43	Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. <i>Molecular Neurobiology</i> , 2018, 55, 1054-1067.	4.0	30
44	Genome-wide analysis of consistently RNA edited sites in human blood reveals interactions with mRNA processing genes and suggests correlations with cell types and biological variables. <i>BMC Genomics</i> , 2018, 19, 963.	2.8	8
45	Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2307-2312.	2.2	7
46	A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs activity and dimerization of GAD67 enzyme. <i>Scientific Reports</i> , 2018, 8, 15470.	3.3	17
47	The effect of childhood trauma on blood transcriptome expression in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2018, 104, 50-54.	3.1	14
48	Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. <i>Neural Plasticity</i> , 2018, 2018, 1-15.	2.2	31
49	Non-Ceruloplasmin Copper Distincts Subtypes in Alzheimerâ€™s Disease: a Genetic Study of ATP7B Frequency. <i>Molecular Neurobiology</i> , 2017, 54, 671-681.	4.0	40
50	The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. <i>Pharmacogenomics Journal</i> , 2017, 17, 146-154.	2.0	37
51	Compound heterozygosity for a hemizygous rare missense variant (rs141999351) and a large CNV deletion affecting the FSTL5 gene in a patient with schizophrenia. <i>Psychiatry Research</i> , 2017, 258, 598-599.	3.3	1
52	Study of the in vitro modulation exerted by the antidepressant drug escitalopram on the expression of candidate microRNAs and their target genes. <i>Molecular and Cellular Neurosciences</i> , 2017, 85, 220-225.	2.2	11
53	Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients. <i>Journal of Affective Disorders</i> , 2017, 208, 443-447.	4.1	15
54	Exome sequencing in schizophrenic patients with high levels of homozygosity identifies novel and extremely rare mutations in the GABA/glutamatergic pathways. <i>PLoS ONE</i> , 2017, 12, e0182778.	2.5	14

#	ARTICLE	IF	CITATIONS
55	Acute Footshock Stress Induces Time-Dependent Modifications of AMPA/NMDA Protein Expression and AMPA Phosphorylation. <i>Neural Plasticity</i> , 2016, 2016, 1-10.	2.2	27
56	Seizure Adequacy Markers and the Prediction of Electroconvulsive Therapy Response. <i>Journal of ECT</i> , 2016, 32, 88-92.	0.6	47
57	Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 277-291.	2.6	18
58	Peripheral whole blood microRNA alterations in major depression and bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 200, 250-258.	4.1	138
59	Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study. <i>Neuropsychobiology</i> , 2016, 74, 15-21.	1.9	8
60	Influence of GRIK4 genetic variants on the electroconvulsive therapy response. <i>Neuroscience Letters</i> , 2016, 626, 94-98.	2.1	10
61	The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia. <i>Current Neuropharmacology</i> , 2016, 14, 540-550.	2.9	16
62	The role of GRIK4 gene in treatment-resistant depression. <i>Genetical Research</i> , 2015, 97, e14.	0.9	19
63	Copper Subtype of Alzheimer Disease: A Genetic Study of ATP7B Frequency. <i>American Journal of Clinical Pathology</i> , 2015, 144, A242-A242.	0.7	0
64	Altered Gene Expression in Schizophrenia: Findings from Transcriptional Signatures in Fibroblasts and Blood. <i>PLoS ONE</i> , 2015, 10, e0116686.	2.5	65
65	MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder. <i>Journal of Affective Disorders</i> , 2015, 183, 179-186.	4.1	17
66	Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder. <i>Translational Psychiatry</i> , 2015, 5, e687-e687.	4.8	26
67	The role of the potassium channel gene KCNK2 in major depressive disorder. <i>Psychiatry Research</i> , 2015, 225, 489-492.	3.3	10
68	Glucose metabolism alterations in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2015, 184, 293-298.	4.1	34
69	Insulin-like Growth Factor 1 Differentially Affects Lithium Sensitivity of Lymphoblastoid Cell Lines from Lithium Responder and Non-responder Bipolar Disorder Patients. <i>Journal of Molecular Neuroscience</i> , 2015, 56, 681-687.	2.3	35
70	Copy number variants in attention-deficit hyperactive disorder. <i>Psychiatric Genetics</i> , 2015, 25, 59-70.	1.1	25
71	Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 461-466.	4.5	34
72	Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 75.	3.7	100

#	ARTICLE	IF	CITATIONS
73	Serum brain-derived neurotrophic factor (BDNF) levels in attention deficit-hyperactivity disorder (ADHD). <i>European Child and Adolescent Psychiatry</i> , 2014, 23, 173-177.	4.7	40
74	Defining an immune signature predictive of glioma progression. <i>Journal of Neuroimmunology</i> , 2014, 275, 35.	2.3	0
75	Heterozygous TREM2 mutations in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2014, 35, 934.e7-934.e10.	3.1	134
76	Understanding phenotype variability in frontotemporal lobar degeneration due to granulin mutation. <i>Neurobiology of Aging</i> , 2014, 35, 1206-1211.	3.1	9
77	Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum. <i>BioTechniques</i> , 2014, 57, 111-114.	1.8	34
78	P4-074: ITALIAN NETWORK FOR AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION (ITALIANDIAFN). , 2014, 10, P810-P810.		0
79	Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1genes. <i>BMC Medical Genetics</i> , 2013, 14, 33.	2.1	26
80	Glucocorticoid-Related Molecular Signaling Pathways Regulating Hippocampal Neurogenesis. <i>Neuropsychopharmacology</i> , 2013, 38, 872-883.	5.4	262
81	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. <i>Alzheimer's and Dementia</i> , 2013, 9, 677-686.	0.8	51
82	Molecular signature of disease onset in Granulin mutation carriers: a gene expression analysis study. <i>Neurobiology of Aging</i> , 2013, 34, 1837-1845.	3.1	19
83	Blood microRNA changes in depressed patients during antidepressant treatment. <i>European Neuropsychopharmacology</i> , 2013, 23, 602-611.	0.7	197
84	Serum Brain-Derived Neurotrophic Factor Levels in Different Neurological Diseases. <i>BioMed Research International</i> , 2013, 2013, 1-7.	1.9	137
85	Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8708-8713.	7.1	272
86	ROLE OF ALLELIC VARIANTS OF FK506-BINDING PROTEIN 51 (FKBP5) GENE IN THE DEVELOPMENT OF ANXIETY DISORDERS. <i>Depression and Anxiety</i> , 2013, 30, 1170-1176.	4.1	42
87	Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline Predictors and Longitudinal Targets. <i>Neuropsychopharmacology</i> , 2013, 38, 377-385.	5.4	372
88	Cannabis and Psychosis: A Systematic Review of Genetic Studies. <i>Current Psychiatry Reviews</i> , 2013, 9, 302-315.	0.9	6
89	Exome Sequencing Followed by Large-Scale Genotyping Suggests a Limited Role for Moderately Rare Risk Factors of Strong Effect in Schizophrenia. <i>American Journal of Human Genetics</i> , 2012, 91, 303-312.	6.2	81
90	Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. <i>Pharmacogenomics Journal</i> , 2012, 12, 68-77.	2.0	92

#	ARTICLE	IF	CITATIONS
91	A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial. <i>Trials</i> , 2012, 13, 73.	1.6	47
92	Biomarkers and Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analyses. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2012, 51, 1003-1019.e20.	0.5	192
93	ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder. <i>BMC Psychiatry</i> , 2012, 12, 145.	2.6	16
94	Possible Influence of a Non-Synonymous Polymorphism Located in the NGF Precursor on Susceptibility to Late-Onset Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 699-705.	2.6	20
95	Atypical presentation of a novel Presenilin 1 R377W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. <i>Neurological Sciences</i> , 2012, 33, 375-378.	1.9	20
96	PCLO gene: Its role in vulnerability to major depressive disorder. <i>Journal of Affective Disorders</i> , 2012, 139, 250-255.	4.1	20
97	Antidepressant Treatments Change 5-HT <sub>2C</sub> Receptor mRNA Expression in Rat Prefrontal/Frontal Cortex and Hippocampus. <i>Neuropsychobiology</i> , 2011, 63, 160-168.	1.9	38
98	Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. <i>Neurochemistry International</i> , 2011, 59, 896-905.	3.8	61
99	Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1322-1325.	4.8	73
100	Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2011, 32, 555.e1-555.e8.	3.1	39
101	Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-9.	2.0	29
102	Alterations of Brain-Derived Neurotrophic Factor Serum Levels in Patients with Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, no-no.	2.4	36
103	BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 323-329.	3.2	54
104	The influence of psychiatric screening in healthy populations selection: a new study and meta-analysis of functional 5-HTTLPR and rs25531 polymorphisms and anxiety-related personality traits. <i>BMC Psychiatry</i> , 2011, 11, 50.	2.6	39
105	Variation in GNB3 predicts response and adverse reactions to antidepressants. <i>Journal of Psychopharmacology</i> , 2011, 25, 867-874.	4.0	44
106	Genetic Background Predicts Poor Prognosis in Frontotemporal Lobar Degeneration. <i>Neurodegenerative Diseases</i> , 2011, 8, 289-295.	1.4	17
107	Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 103.	2.1	82
108	Polymorphic CA repeat in IGF-I gene: lack of association with schizophrenia. <i>Psychiatric Genetics</i> , 2010, 20, 44-45.	1.1	4

#	ARTICLE	IF	CITATIONS
109	VEGF Haplotypes are Associated with Increased Risk to Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 87-94.	2.6	12
110	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. <i>Journal of Neurology</i> , 2010, 257, 2004-2014.	3.6	44
111	Reduced function of the serotonin transporter is associated with decreased expression of BDNF in rodents as well as in humans. <i>Neurobiology of Disease</i> , 2010, 37, 747-755.	4.4	107
112	BDNF Val66Met polymorphism and protein levels in Amniotic Fluid. <i>BMC Neuroscience</i> , 2010, 11, 16.	1.9	16
113	Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients: A case-control study. <i>Journal of Affective Disorders</i> , 2010, 122, 174-178.	4.1	76
114	New Copy Number Variations in Schizophrenia. <i>PLoS ONE</i> , 2010, 5, e13422.	2.5	82
115	Genetic Variations and Association. <i>International Review of Neurobiology</i> , 2010, 94, 129-151.	2.0	0
116	The MCP-1 Gene (SCYA2) and Mood Disorders: Preliminary Results of a Case-Control Association Study. <i>NeuroImmunoModulation</i> , 2010, 17, 126-131.	1.8	35
117	Serum and plasma BDNF levels in major depression: A replication study and meta-analyses. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 763-773.	2.6	363
118	Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: Comparison with methylphenidate. <i>Pharmacological Research</i> , 2010, 62, 523-529.	7.1	60
119	Clinical and medial temporal features in a family with mood disorders. <i>Neuroscience Letters</i> , 2010, 468, 93-97.	2.1	23
120	Serotonin transporter gene polymorphisms and treatment-resistant depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 934-939.	4.8	38
121	The Expression of VGF is Reduced in Leukocytes of Depressed Patients and it is Restored by Effective Antidepressant Treatment. <i>Neuropsychopharmacology</i> , 2010, 35, 1423-1428.	5.4	68
122	Long-Term Duloxetine Treatment Normalizes Altered Brain-Derived Neurotrophic Factor Expression in Serotonin Transporter Knockout Rats through the Modulation of Specific Neurotrophin Isoforms. <i>Molecular Pharmacology</i> , 2010, 77, 846-853.	2.3	56
123	A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia. <i>PLoS Genetics</i> , 2009, 5, e1000373.	3.5	383
124	An Association of GRIK3 Ser310Ala Functional Polymorphism with Personality Traits. <i>Neuropsychobiology</i> , 2009, 59, 28-33.	1.9	16
125	Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants. <i>BMC Neuroscience</i> , 2009, 10, 48.	1.9	53
126	Mutation within <i>TARDBP</i> leads to Frontotemporal Dementia without motor neuron disease. <i>Human Mutation</i> , 2009, 30, E974-E983.	2.5	220



#	ARTICLE	IF	CITATIONS
127	Genetic Variation in the G720/G30 Gene Locus (DAOA) Influences the Occurrence of Psychotic Symptoms in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 953-960.	2.6	24
128	VEGF serum levels in depressed patients during SSRI antidepressant treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 146-149.	4.8	61
129	Acute Stress Responsiveness of the Neurotrophin BDNF in the Rat Hippocampus is Modulated by Chronic Treatment with the Antidepressant Duloxetine. <i>Neuropsychopharmacology</i> , 2009, 34, 1523-1532.	5.4	104
130	Markers of Alzheimer's disease in a population attending a memory clinic. <i>Alzheimer's and Dementia</i> , 2009, 5, 307-317.	0.8	80
131	Association study and mutational screening of SYNGR1 as a candidate susceptibility gene for schizophrenia. <i>Psychiatric Genetics</i> , 2009, 19, 237-243.	1.1	12
132	Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. <i>Neurogenetics</i> , 2008, 9, 197-205.	1.4	63
133	Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 745-753.	1.7	31
134	Reduced activation of intracellular signaling pathways in rat prefrontal cortex after chronic phencyclidine administration. <i>Pharmacological Research</i> , 2008, 57, 296-302.	7.1	14
135	Effect of the XbaI polymorphism of estrogen receptor alpha on postmenopausal gray matter. <i>Neuroscience Letters</i> , 2008, 434, 304-309.	2.1	8
136	5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. <i>Neuroscience Letters</i> , 2008, 437, 130-134.	2.1	79
137	Serum leptin levels are higher in females affected by frontotemporal lobar degeneration than Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 79, 712-715.	1.9	12
138	Chronic Duloxetine Treatment Induces Specific Changes in the Expression of BDNF Transcripts and in the Subcellular Localization of the Neurotrophin Protein. <i>Neuropsychopharmacology</i> , 2007, 32, 2351-2359.	5.4	110
139	Risk Prediction for Clinical Phenotype in Myotonic Dystrophy Type 1: Data from 2,650 Patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2007, 11, 84-90.	1.7	46
140	Further evidence on the lack of association between glycogen synthase kinase 3 $\beta$ gene polymorphisms and bipolar disorder. <i>Psychiatric Genetics</i> , 2007, 17, 249-250.	1.1	6
141	A putative regulatory subunit (NR3A) of the NMDA receptor complex as candidate gene for susceptibility to schizophrenia: a case-control study. <i>Psychiatric Genetics</i> , 2007, 17, 355-356.	1.1	5
142	Long-term soluble A $\beta$ 1-40 activates CaM kinase II in organotypic hippocampal cultures. <i>Neurobiology of Aging</i> , 2007, 28, 1388-1395.	3.1	10
143	-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study. <i>Brain, Behavior, and Immunity</i> , 2007, 21, 450-457.	4.1	44
144	Dementia, delusions and seizures: storage disease or genetic AD?. <i>European Journal of Neurology</i> , 2007, 14, 1057-1059.	3.3	31

#	ARTICLE	IF	CITATIONS
145	Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. <i>European Neuropsychopharmacology</i> , 2006, 16, 620-624.	0.7	149
146	Regulation of Editing and Expression of Glutamate $\hat{\pm}$ -Amino-Propionic-Acid (AMPA)/Kainate Receptors by Antidepressant Drugs. <i>Biological Psychiatry</i> , 2006, 59, 713-720.	1.3	92
147	The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder. <i>Neuroscience Letters</i> , 2006, 406, 133-137.	2.1	58
148	No association between Ala9Val functional polymorphism of MnSOD gene and schizophrenia in a representative Italian sample. <i>Neuroscience Letters</i> , 2006, 410, 208-211.	2.1	12
149	No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 371-378.	2.6	30
150	Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. <i>European Journal of Human Genetics</i> , 2006, 14, 443-449.	2.8	33
151	Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. <i>Journal of Affective Disorders</i> , 2006, 91, 83-86.	4.1	137
152	MCP-1 gene (SCYA2) and schizophrenia: A case-control association study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2005, 132B, 1-4.	1.7	39
153	Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression?. <i>Clinical Neurophysiology</i> , 2005, 116, 1062-1071.	1.5	78
154	Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence. <i>Cytokine</i> , 2005, 30, 293-302.	3.2	58
155	Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. <i>Neurobiology of Aging</i> , 2005, 26, 455-464.	3.1	43
156	Lack of association between MnSOD gene polymorphism and sporadic Alzheimer's Disease. <i>Aging Clinical and Experimental Research</i> , 2005, 17, 445-448.	2.9	9
157	Selective Phosphorylation of Nuclear CREB by Fluoxetine is Linked to Activation of CaM Kinase IV and MAP Kinase Cascades. <i>Neuropsychopharmacology</i> , 2004, 29, 1831-1840.	5.4	171
158	Association Study of $\hat{\epsilon}$ 1727 A/T, $\hat{\epsilon}$ 50 C/T and (CAA) <sub>n</sub> Repeat GSK-3 $\hat{\beta}$ Gene Polymorphisms with Schizophrenia. <i>Neuropsychobiology</i> , 2004, 50, 16-20.	1.9	29
159	Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. <i>Biological Psychiatry</i> , 2004, 55, 1095-1102.	1.3	99
160	Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 356, 119-122.	2.1	49
161	3 $\hat{\epsilon}$ UTR (AGC) <sub>n</sub> repeat of glial cell line-derived neurotrophic factor (GDNF) gene polymorphism in schizophrenia. <i>Neuroscience Letters</i> , 2004, 357, 235-237.	2.1	24
162	Expression and phosphorylation of $\hat{\gamma}$ -CaM kinase II in cultured Alzheimer fibroblasts. <i>Neurobiology of Aging</i> , 2004, 25, 1187-1196.	3.1	7

#	ARTICLE	IF	CITATIONS
163	Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. <i>NeuroReport</i> , 2004, 15, 2109-2112.	1.2	66
164	Antidepressants activate CaMKII in neuron cell body by Thr286 phosphorylation. <i>NeuroReport</i> , 2004, 15, 2393-2396.	1.2	37
165	Association between IL-1 $\beta$ -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. <i>Journal of Psychiatric Research</i> , 2003, 37, 457-462.	3.1	52
166	Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity. <i>Journal of Neuroscience Research</i> , 2003, 72, 622-628.	2.9	68
167	Dopaminergic D2 receptor activation modulates FGF $\beta$ gene expression in rat prefrontal cortex and hippocampus. <i>Journal of Neuroscience Research</i> , 2003, 74, 74-80.	2.9	26
168	Atypical dementia associated with a novel presenilin $\beta$ mutation. <i>Annals of Neurology</i> , 2003, 54, 832-836.	5.3	51
169	Selective regulation of presynaptic Calcium/Calmodulin-Dependent protein kinase II by psychotropic drugs. <i>Biological Psychiatry</i> , 2003, 53, 442-449.	1.3	36
170	Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. <i>Biological Psychiatry</i> , 2003, 53, 617-619.	1.3	57
171	Methylenetetrahydrofolate reductase and angiotensin converting enzyme gene polymorphisms in two genetically and diagnostically distinct cohort of Alzheimer patients. <i>Neurobiology of Aging</i> , 2003, 24, 933-939.	3.1	58
172	Allelic Variation in the Human Prodynorphin Gene Promoter and Schizophrenia. <i>Neuropsychobiology</i> , 2002, 46, 17-21.	1.9	27
173	Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. <i>Biological Psychiatry</i> , 2002, 51, 480-484.	1.3	81
174	Epidemiology of myotonic dystrophy in Italy: re-appraisal after genetic diagnosis. <i>Clinical Genetics</i> , 2002, 59, 344-349.	2.0	48
175	Modulation of synaptic plasticity by stress and antidepressants. <i>Bipolar Disorders</i> , 2002, 4, 166-182.	1.9	110
176	Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. <i>Biological Psychiatry</i> , 2001, 50, 117-122.	1.3	50
177	Long-term treatment with s-adenosylmethionine induces changes in presynaptic cam kinase II and synapsin I. <i>Biological Psychiatry</i> , 2001, 50, 337-344.	1.3	11
178	Human Y-chromosome variation in the Western Mediterranean area: implications for the peopling of the region. <i>Human Immunology</i> , 2001, 62, 871-884.	2.4	79
179	Modulation of fibroblast growth factor-2 by stress and corticosteroids: from developmental events to adult brain plasticity. <i>Brain Research Reviews</i> , 2001, 37, 249-258.	9.0	92
180	Decreased hippocampal BDNF expression after acute systemic injection of quinpirole. <i>Neuropharmacology</i> , 2001, 40, 954-957.	4.1	11

#	ARTICLE	IF	CITATIONS
181	Combined $\alpha$ 1- and $\alpha$ 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle. <i>Psychopharmacology</i> , 2001, 159, 105-110.	3.1	16
182	Stimulatory role of dopamine on fibroblast growth factor-2 expression in rat striatum. <i>Journal of Neurochemistry</i> , 2001, 76, 990-997.	3.9	48
183	Association between $\alpha$ 1G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. <i>Molecular Psychiatry</i> , 2001, 6, 79-82.	7.9	172
184	Serine/threonine kinases as molecular targets of antidepressants: implications for pharmacological treatment and pathophysiology of affective disorders. , 2001, 89, 149-170.		28
185	Prenatal Diagnosis of Myotonic Dystrophy Using Fetal DNA Obtained from Maternal Plasma. <i>Clinical Chemistry</i> , 2000, 46, 301-302.	3.2	201
186	Myotonic dystrophy: tissue-specific effect of somatic CTG expansions on allele-specific DMAHP/SIX5 expression. <i>Human Molecular Genetics</i> , 1999, 8, 1017-1023.	2.9	38
187	Reduction of the DM-associated homeo domain protein (DMAHP) mRNA in different brain areas of myotonic dystrophy patients. <i>Neuromuscular Disorders</i> , 1999, 9, 215-219.	0.6	18
188	Cognitive impairment and (CTG) <sub>n</sub> expansion in myotonic dystrophy patients. <i>Biological Psychiatry</i> , 1999, 46, 425-431.	1.3	67
189	Genomic instability associated with myotonic dystrophy does not involve p53 expression and activity. , 1998, 16, 117-122.		3
190	A Single Polymerase Chain Reaction-Based Protocol for Detecting Normal and Expanded Alleles in Myotonic Dystrophy. <i>Diagnostic Molecular Pathology</i> , 1998, 7, 135-137.	2.1	27
191	Expression of receptors for native and chemically modified low-density lipoproteins in brain microvessels. <i>FEBS Letters</i> , 1997, 401, 53-58.	2.8	35
192	Expression Study of Survival Motor Neuron Gene in Human Fetal Tissues. <i>Biochemical and Molecular Medicine</i> , 1997, 61, 102-106.	1.4	31
193	Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 59-65.	0.1	28
194	Correlation of SfiI macrorestriction endonuclease fingerprint analysis of <i>Candida parapsilosis</i> isolates with source of isolation. <i>Journal of Medical Microbiology</i> , 1996, 45, 173-178.	1.8	19
195	Assignment of the hexokinase type 3 gene (HK3) to human chromosome band 5q35.3 by somatic cell hybrids and in situ hybridization. <i>Cytogenetic and Genome Research</i> , 1996, 74, 187-188.	1.1	5
196	Two pedigrees of autosomal dominant atrioventricular canal defect (AVCD): Exclusion from the critical region on 8p. <i>American Journal of Medical Genetics Part A</i> , 1995, 57, 483-488.	2.4	18
197	Postzygotic instability of the myotonic dystrophy p[AGC] <sub>n</sub> repeat supported by larger expansions in muscle and reduced amplifications in sperm. <i>Journal of Neurology</i> , 1995, 242, 379-383.	3.6	13
198	Myotonic dystrophy: evidence for a possible dominant-negative RNA mutation. <i>Human Molecular Genetics</i> , 1995, 4, 599-606.	2.9	179

#	ARTICLE	IF	CITATIONS
199	Discordant clinical outcome in myotonic dystrophy relatives showing (CTG) <sub>n</sub> > 700 repeats. <i>Neuromuscular Disorders</i> , 1995, 5, 157-159.	0.6	21
200	Identification of Multiple Transcribed Sequences from the Spinal Muscular Atrophy Region on Human Chromosome 5. <i>Biochemical and Biophysical Research Communications</i> , 1995, 206, 294-301.	2.1	7
201	Survival Motor-Neuron Gene Transcript Analysis in Muscles from Spinal Muscular-Atrophy Patients. <i>Biochemical and Biophysical Research Communications</i> , 1995, 213, 342-348.	2.1	182
202	Different Expression of the Myotonin Protein Kinase Gene in Discrete Areas of Human Brain. <i>Biochemical and Biophysical Research Communications</i> , 1995, 216, 489-494.	2.1	9
203	Exclusion of linkage with chromosome 21 in families with recurrence of non-Down's atrioventricular canal. <i>Human Genetics</i> , 1994, 94, 708-10.	3.8	14
204	First-trimester prenatal diagnosis of spinal muscular atrophy using microsatellite markers. <i>Prenatal Diagnosis</i> , 1994, 14, 459-462.	2.3	12
205	North Eurasian origin of the myotonic dystrophy mutation. <i>Human Mutation</i> , 1994, 4, 79-81.	2.5	6
206	High conservation of the trinucleotide [CTG] <sub>n</sub> repeat at the myotonic dystrophy locus in nonhuman primates. <i>Human Evolution</i> , 1994, 9, 315-321.	2.0	0
207	Male Hypogonadism in Myotonic Dystrophy is Related to (Ctg) <sub>N</sub> Triplet Mutation. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 381-383.	3.3	37
208	(CTG) <sub>n</sub> Triplet Mutation and Phenotype Manifestations in Myotonic Dystrophy Patients. <i>Biochemical Medicine and Metabolic Biology</i> , 1993, 50, 85-92.	0.7	47
209	Human Elongation Factor EF-1 <sup>2</sup> : Cloning and Characterization of the EF1 <sup>25a</sup> Gene and Assignment of EF-1 <sup>2</sup> Isoforms to Chromosomes 2, 5, 15, and X. <i>Biochemical and Biophysical Research Communications</i> , 1993, 197, 154-162.	2.1	23
210	A tool for the molecular analysis of an early lethal disease: slide-PCR in spinal muscular atrophy patients. <i>Molecular and Cellular Probes</i> , 1993, 7, 221-226.	2.1	7
211	Focus The dynamic genomics of myotonic dystrophy and its clinical relevance: an overview. <i>Biomedicine and Pharmacotherapy</i> , 1993, 47, 321-330.	5.6	5
212	Expansion of the myotonic dystrophy gene in Italian and Spanish patients.. <i>Journal of Medical Genetics</i> , 1992, 29, 789-790.	3.2	8
213	Inosine-containing primers in human papillomavirus detection by polymerase chain reaction. <i>Biomedicine and Pharmacotherapy</i> , 1992, 46, 167-169.	5.6	6
214	Assignment of the slow troponin T (TNNT1) gene to chromosome 19 using polymerase chain reaction. <i>Human Genetics</i> , 1992, 88, 697-698.	3.8	5
215	Analysis of apoB, HLADQ alpha, and D1S80 polymorphisms in the Italian population using the polymerase chain reaction. <i>American Journal of Human Biology</i> , 1992, 4, 381-386.	1.6	17
216	Genotyping of spinal muscular atrophy families with linked DNA probes. <i>Clinical Genetics</i> , 1992, 42, 317-319.	2.0	2

#	ARTICLE	IF	CITATIONS
217	Study of the effects on DNA of electromagnetic fields using clamped homogeneous electric field gel electrophoresis. <i>Biomedicine and Pharmacotherapy</i> , 1991, 45, 451-454.	5.6	5
218	3? creatine kinase (M-type) polymorphisms linked to myotonic dystrophy in Italian and Spanish populations. <i>Human Genetics</i> , 1991, 87, 654-6.	3.8	10